{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:46Z","timestamp":1747207366834,"version":"3.40.5"},"reference-count":65,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2021,3,24]]},"abstract":"<jats:sec>\n<jats:title>Background::<\/jats:title>\n<jats:p> Hepatitis C virus (HCV) infection is still one of the leading causes of chronic liver disease,\nwith chronically infected making up approximately 1% of the global population. Of those infected, 70%\n(55-85%) will develop chronic HCV infection. Chronic HCV infection causes substantial morbidity and mortality,\nwith complications including cirrhosis, end-stage liver disease, hepatocellular carcinoma, and eventually\ndeath.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective::<\/jats:title>\n<jats:p>Therapeutic options for chronic HCV infection have evolved dramatically since 2014, with a translation\nfrom pegylated interferon and ribavirin (associated with suboptimal cure and high treatment-related toxicity)\nto oral direct-acting antiviral treatment. There are four classes of direct-acting antivirals which differ by\ntheir mechanism of action and therapeutic target. They are all pointed to proteins that form the cytoplasmic viral\nreplication complex. Multiple studies have demonstrated that direct-acting antiviral therapy is extremely\nwell tolerated, highly efficacious, with few side effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods::<\/jats:title>\n<jats:p>We performed an indexed MEDLINE search with keywords regarding specific direct-acting antiviral\nregimes and their pharmacokinetics, drug-drug interactions, and metabolism in specific settings of pregnancy,\nlactation, liver cirrhosis, liver transplantation and HCC risk, kidney failure and kidney transplantation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results::<\/jats:title>\n<jats:p>We present a comprehensive overview of specific direct-acting antiviral metabolism and drug-drug interaction\nissues in different settings.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion::<\/jats:title>\n<jats:p>Despite its complex pharmacokinetics and the possibility of drug-drug interactions, direct-acting\nantivirals are highly efficacious in providing viral clearance, which is an obvious advantage compared to possible\ninteractions or side effects. They should be administered cautiously in patients with other comorbidities,\nand with tight control of immunosuppressive therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200221999201214224126","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T10:54:09Z","timestamp":1608029649000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-0642","authenticated-orcid":true,"given":"Ivana","family":"Mikolasevic","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, University Hospital Merkur, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9828-8916","authenticated-orcid":true,"given":"Tajana F.","family":"Kanizaj","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Merkur, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-4203","authenticated-orcid":true,"given":"Dorotea","family":"Bozic","sequence":"additional","affiliation":[{"name":"Department for Gastroenterology and Hepatology, University Hospital Center, Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6835-2369","authenticated-orcid":true,"given":"Petra","family":"Puz","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, General Hospital Koprivnica, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-3003","authenticated-orcid":true,"given":"Sanja S.","family":"Shapeski","sequence":"additional","affiliation":[{"name":"School of Medicine, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3465-4227","authenticated-orcid":true,"given":"Zeljko","family":"Puljiz","sequence":"additional","affiliation":[{"name":"Department for Gastroenterology and Hepatology, University Hospital Center, Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-7808","authenticated-orcid":true,"given":"Delfa","family":"Radic-Kristo","sequence":"additional","affiliation":[{"name":"School of Medicine, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-9079","authenticated-orcid":true,"given":"Milos","family":"Lalovac","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Merkur, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-1013","authenticated-orcid":true,"given":"Maja","family":"Mijic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Merkur, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-3738","authenticated-orcid":true,"given":"Bozena","family":"Delija","sequence":"additional","affiliation":[{"name":"School of Medicine, University Center Hospital Rijeka, Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7175-6249","authenticated-orcid":true,"given":"Toni","family":"Juric","sequence":"additional","affiliation":[{"name":"School of Medicine, University Center Hospital Rijeka, Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-1725","authenticated-orcid":true,"given":"Ivan","family":"Bogadi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Merkur, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-8223","authenticated-orcid":true,"given":"Lucija","family":"Virovic-Jukic","sequence":"additional","affiliation":[{"name":"School of Medicine, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"year":"2017","key":"ref=1","unstructured":"Global Hepatitis report. World Health OrganizationAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\"> https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en2017"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"Shepard C.W.","year":"2005","unstructured":"Shepard C.W.; Finelli L.; Alter M.J.; Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005,5(9),558-567","journal-title":"Lancet Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","year":"2018","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol European Association for the Study of the Liver2018,69(2),461-511","journal-title":"J Hepatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2105\/AJPH.86.5.655","volume":"86","author":"Garfein R.S.","year":"1996","unstructured":"Garfein R.S.; Vlahov D.; Galai N.; Doherty M.C.; Nelson K.E.; Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996,86(5),655-661","journal-title":"Am J Public Health"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF03405102","volume":"91","author":"Patrick D.M.","year":"2000","unstructured":"Patrick D.M.; Buxton J.A.; Bigham M.; Mathias R.G.; Public health and hepatitis C. Can J Public Health 2000,91(Suppl. 1),S18-S21, S19-S23","journal-title":"Can J Public Health"},{"key":"ref=6","first-page":"S173","volume":"36","author":"Jonas M.M.","year":"2002","unstructured":"Jonas M.M.; Children with hepatitis C. Hepatology 2002,36(5)(Suppl. 1),S173-S178","journal-title":"Hepatology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3109\/00365549509047042","volume":"27","author":"Mele A.","year":"1995","unstructured":"Mele A.; Corona R.; Tosti M.E.; Palumbo F.; Moiraghi A.; Novaco F.; Galanti C.; Bernacchia R.; Ferraro P.; Beauty treatments and risk of parenterally transmitted hepatitis: results from the hepatitis surveillance system in Italy. Scand J Infect Dis 1995,27(5),441-444","journal-title":"Scand J Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1055\/s-2007-1007260","volume":"15","author":"Mansell C.J.","year":"1995","unstructured":"Mansell C.J.; Locarnini S.A.; Epidemiology of hepatitis C in the East. Semin Liver Dis 1995,15(1),15-32","journal-title":"Semin Liver Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1126\/science.1279801","volume":"258","author":"Farci P.","year":"1992","unstructured":"Farci P.; Alter H.J.; Govindarajan S.; Wong D.C.; Engle R.; Lesniewski R.R.; Mushahwar I.K.; Desai S.M.; Miller R.H.; Ogata N.; Lack of protective immunity against reinfection with hepatitis C virus. Science 1992,258(5079),135-140","journal-title":"Science"},{"key":"ref=10","first-page":"402","volume":"22","author":"Yuki N.","year":"1995","unstructured":"Yuki N.; Hayashi N.; Ohkawa K.; Hagiwara H.; Oshita M.; Katayama K.; Sasaki Y.; Kasahara A.; Fusamoto H.; Kamada T.; The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C. Hepatology 1995,22(2),402-406","journal-title":"Hepatology"},{"key":"ref=11","first-page":"1332","author":"Wedemeyer H.","year":"2016","unstructured":"Wedemeyer H.; Hepatitis C.; Sleisenger and Fordtran\u2019s gastrointestinal and liver disease 10 ed. Feldman, M.; Friedman, L.; Brandt, L., Ed; Saunders: Philadelphia, 2016,1332-1352"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","volume":"19","author":"Poordad F.","year":"2012","unstructured":"Poordad F.; Dieterich D.; Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012,19(7),449-464","journal-title":"J Viral Hepat"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"Zeuzem S.","year":"2014","unstructured":"Zeuzem S.; Dusheiko G.M.; Salupere R.; Mangia A.; Flisiak R.; Hyland R.H.; Illeperuma A.; Svarovskaia E.; Brainard D.M.; Symonds W.T.; Subramanian G.M.; McHutchison J.G.; Weiland O.; Reesink H.W.; Ferenci P.; H\u00e9zode C.; Esteban R.; VALENCE Investigators. SOF and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014,370,1993-2001","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"Kowdley K.V.","year":"2014","unstructured":"Kowdley K.V.; Gordon S.C.; Reddy K.R.; Rossaro L.; Bernstein D.E.; Lawitz E.; Shiffman M.L.; Schiff E.; Ghalib R.; Ryan M.; Rustgi V.; Chojkier M.; Herring R.; Di Bisceglie A.M.; Pockros P.J.; Subramanian G.M.; An D.; Svarovskaia E.; Hyland R.H.; Pang P.S.; Symonds W.T.; McHutchison J.G.; Muir A.J.; Pound D.; Fried M.W.; ION-3 Investigators. LDV and SOF for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014,370,1879-1888","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"Nelson D.R.","year":"2015","unstructured":"Nelson D.R.; Cooper J.N.; Lalezari J.P.; Lawitz E.; Pockros P.J.; Gitlin N.; Freilich B.F.; Younes Z.H.; Harlan W.; Ghalib R.; Oguchi G.; Thuluvath P.J.; Ortiz-Lasanta G.; Rabinovitz M.; Bernstein D.; Bennett M.; Hawkins T.; Ravendhran N.; Sheikh A.M.; Varunok P.; Kowdley K.V.; Hennicken D.; McPhee F.; Rana K.; Hughes E.A.; All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology ALLY-3 Study Team2015,61(4),1127-1135","journal-title":"Hepatology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/ajg.2016.99","volume":"111","author":"Younossi Z.M.","year":"2016","unstructured":"Younossi Z.M.; Stepanova M.; Henry L.; Nader F.; Hunt S.; An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 2016,111(6),808-816","journal-title":"Am J Gastroenterol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1086\/380203","volume":"189","author":"Lerat H.","year":"2004","unstructured":"Lerat H.; Hollinger F.B.; Hepatitis C virus (HCV) occult infection or occult HCV RNA detection? J Infect Dis 2004,189(1),3-6","journal-title":"J Infect Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2007.12.011","volume":"134","author":"Pham T.N.","year":"2008","unstructured":"Pham T.N.; King D.; Macparland S.A.; McGrath J.S.; Reddy S.B.; Bursey F.R.; Michalak T.I.; Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008,134(3),812-822","journal-title":"Gastroenterology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3748\/wjg.v13.i17.2406","volume":"13","author":"Dubuisson J.","year":"2007","unstructured":"Dubuisson J.; Hepatitis C virus proteins. World J Gastroenterol 2007,13(17),2406-2415","journal-title":"World J Gastroenterol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"20509","DOI":"10.1073\/pnas.1105797108","volume":"108","author":"Powdrill M.H.","year":"2011","unstructured":"Powdrill M.H.; Tchesnokov E.P.; Kozak R.A.; Russell R.S.; Martin R.; Svarovskaia E.S.; Mo H.; Kouyos R.D.; G\u00f6tte M.; Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 2011,108(51),20509-20513","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40262-018-0710-1","volume":"58","author":"Smolders E.J.","year":"2019","unstructured":"Smolders E.J.; Ter Horst P.J.G.; Wolters S.; Burger D.M.; Cardiovascular risk management and hepatitis C: combining drugs. Clin Pharmacokinet 2019,58(5),565-592","journal-title":"Clin Pharmacokinet"},{"key":"ref=22","unstructured":"HEP drug interactions. University of LiverpoolAvailable at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.hep-druginteractions.org\/checker\"> https:\/\/www.hep-druginteractions.org\/checker"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bcp.13095","volume":"83","author":"Talavera Pons S.","year":"2017","unstructured":"Talavera Pons S.; Boyer A.; Lamblin G.; Chennell P.; Ch\u00e2tenet F-T.; Nicolas C.; Sautou V.; Abergel A.; Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol 2017,83(2),269-293","journal-title":"Br J Clin Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","volume":"58","author":"Smolders E.J.","year":"2019","unstructured":"Smolders E.J.; Jansen A.M.E.; Ter Horst P.G.J.; Rockstroh J.; Back D.J.; Burger D.M.; Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet 2019,58(10),1237-1263","journal-title":"Clin Pharmacokinet"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.10.014","volume":"56","author":"N\u00e9ant N.","year":"2020","unstructured":"N\u00e9ant N.; Solas C.; Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis C virus infection. Int J Antimicrob Agents [Online early access].2020,56(1)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"H\u00f6ner Zu Siederdissen C.","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen C.; Maasoumy B.; Marra F.; Deterding K.; Port K.; Manns M.P.; Cornberg M.; Back D.; Wedemeyer H.; Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real- world cohort. Clin Infect Dis 2016,62(5),561-567","journal-title":"Clin Infect Dis"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172159","volume":"12","author":"Kondili L.A.","year":"2017","unstructured":"Kondili L.A.; Gaeta G.B.; Ieluzzi D.; Zignego A.L.; Monti M.; Gori A.; Soria A.; Raimondo G.; Filomia R.; Di Leo A.; Iannone A.; Massari M.; Corsini R.; Gulminetti R.; Gatti Comini A.; Toniutto P.; Dissegna D.; Russo F.P.; Zanetto A.; Rumi M.G.; Brancaccio G.; Danieli E.; Brunetto M.R.; Weimer L.E.; Quaranta M.G.; Vella S.; Puoti M.; Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One [Online].2017,12(2)","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","volume":"23","author":"Langness J.A.","year":"2017","unstructured":"Langness J.A.; Nguyen M.; Wieland A.; Everson G.T.; Kiser J.J.; Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017,23(9),1618-1626","journal-title":"World J Gastroenterol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1177\/1060028018766507","volume":"52","author":"Ottman A.A.","year":"2018","unstructured":"Ottman A.A.; Townsend M.L.; Hashem M.G.; DiMondi V.P.; Britt R.B.; Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic hepatitis C infection. Ann Pharmacother 2018,52(8),763-768","journal-title":"Ann Pharmacother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/apt.13769","volume":"44","author":"Vermehren J.","year":"2016","unstructured":"Vermehren J.; Peiffer K.H.; Welsch C.; Grammatikos G.; Welker M.W.; Weiler N.; Zeuzem S.; Welzel T.M.; Sarrazin C.; The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2016,44(8),856-865","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.18553\/jmcp.2019.25.11.1261","volume":"25","author":"Keast S.L.","year":"2019","unstructured":"Keast S.L.; Holderread B.; Cothran T.; Skrepnek G.H.; Hepatitis C.; Hepatitis C direct-acting antiviral treatment selection, treatment failure, and use of drug-drug interactions in a state medicaid program. J Manag Care Spec Pharm 2019,25(11),1261-1267","journal-title":"J Manag Care Spec Pharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1124\/dmd.117.079038","volume":"46","author":"Garrison K.L.","year":"2018","unstructured":"Garrison K.L.; German P.; Mogalian E.; Mathias A.; The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos 2018,46(8),1212-1225","journal-title":"Drug Metab Dispos"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.drudis.2019.01.003","volume":"24","author":"Yu G.","year":"2019","unstructured":"Yu G.; Zheng Y.; Yu Y.; Li G.F.; Derendorf H.; Gastric-acid-mediated drug-drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies. Drug Discov Today 2019,24(3),845-857","journal-title":"Drug Discov Today"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/liv.14283","volume":"40","author":"Ing Lorenzini K.","year":"2020","unstructured":"Ing Lorenzini K.; Girardin F.; Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients. Liver Int 2020,40(1),32-44","journal-title":"Liver Int"},{"key":"ref=35","first-page":"13","volume":"28","author":"Christensen S.","year":"2019","unstructured":"Christensen S.; Buggisch P.; Mauss S.; B\u00f6ker K.H.; M\u00fcller T.; Klinker H.; Zimmermann T.; Serfert Y.; Weber B.; Reimer J.; Wedemeyer H.; Alcohol and cannabis consumption does not diminish cure rates in a real- world cohort of chronic hepatitis C virus infected patients on opioid substitution therapy-data from the German Hepatitis C-Registry [DHC-R]. Subst Abuse 2019,28,13","journal-title":"Subst Abuse"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"e00958-17","DOI":"10.1128\/AAC.00958-17","volume":"61","author":"Kosloski M.P.","year":"2017","unstructured":"Kosloski M.P.; Zhao W.; Asatryan A.; Kort J.; Geoffroy P.; Liu W.; No clinically relevant drug-drug interactions between methadone or buprenorphine-naloxone and antiviral combination GLE and PIB. Antimicrob Agents Chemother 2017,61,e00958-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","volume":"66","author":"Grebely J.","year":"2019","unstructured":"Grebely J.; Dore G.J.; Alami N.N.; Conway B.; Dillon J.F.; Gschwantler M.; Felizarta F.; H\u00e9zode C.; Tomasiewicz K.; Fredrick L.M.; Dumas E.O.; Safety and efficacy of GLE\/PIB in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy 2019,66,73-79","journal-title":"Int J Drug Policy"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2016.10.021","volume":"169","author":"Tsui J.I.","year":"2016","unstructured":"Tsui J.I.; Williams E.C.; Green P.K.; Berry K.; Su F.; Ioannou G.N.; Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend 2016,169,101-109","journal-title":"Drug Alcohol Depend"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jceh.2016.05.006","volume":"6","author":"Yeoh S.W.","year":"2016","unstructured":"Yeoh S.W.; Iatrogenic cushing syndrome from interaction between ritonavir and oral budesonide during direct acting antiviral hepatitis C therapy. J Clin Exp Hepatol 2016,6(3),246-249","journal-title":"J Clin Exp Hepatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1017\/S0950268817001947","volume":"145","author":"Hofstraat S.H.I.","year":"2017","unstructured":"Hofstraat S.H.I.; Falla A.M.; Duffell E.F.; Hahn\u00e9 S.J.M.; Amato-Gauci A.J.; Veldhuijzen I.K.; Tavoschi L.; Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU\/EEA: a systematic review. Epidemiol Infect 2017,145(14),2873-2885","journal-title":"Epidemiol Infect"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/cid\/ciu447","volume":"59","author":"Benova L.","year":"2014","unstructured":"Benova L.; Mohamoud Y.A.; Calvert C.; Abu-Raddad L.J.; Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014,59(6),765-773","journal-title":"Clin Infect Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4254\/wjh.v8.i12.557","volume":"8","author":"Spera A.M.","year":"2016","unstructured":"Spera A.M.; Eldin T.K.; Tosone G.; Orlando R.; Antiviral therapy for hepatitis C: Has anything changed for pregnant\/lactating women? World J Hepatol 2016,8(12),557-565","journal-title":"World J Hepatol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.semperi.2015.08.003","volume":"39","author":"Feghali M.","year":"2015","unstructured":"Feghali M.; Venkataramanan R.; Caritis S.; Pharmacokinetics of drugs in pregnancy. Semin Perinatol 2015,39(7),512-519","journal-title":"Semin Perinatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/apt.15476","volume":"50","author":"Freriksen J.J.M.","year":"2019","unstructured":"Freriksen J.J.M.; van Seyen M.; Judd A.; Gibb D.M.; Collins I.J.; Greupink R.; Russel F.G.M.; Drenth J.P.H.; Colbers A.; Burger D.M.; Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. Aliment Pharmacol Ther 2019,50(7),738-750","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/bcp.13432","volume":"83","author":"Schalkwijk S.","year":"2017","unstructured":"Schalkwijk S.; Greupink R.; Burger D.; Free dug concentrations in pregnancy: Bound to measure unbound? Br J Clin Pharmacol 2017,83(12),2595-2598","journal-title":"Br J Clin Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/GRF.0000000000000142","volume":"58","author":"Newton E.R.","year":"2015","unstructured":"Newton E.R.; Hale T.W.; Drugs in breast milk. Clin Obstet Gynecol 2015,58(4),868-884","journal-title":"Clin Obstet Gynecol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jhep.2017.03.006","volume":"67","author":"Belli L.S.","year":"2017","unstructured":"Belli L.S.; Duvoux C.; Berenguer M.; Berg T.; Coilly A.; Colle I.; Fagiuoli S.; Khoo S.; Pageaux G.P.; Puoti M.; Samuel D.; Strazzabosco M.; ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol 2017,67(3),585-602","journal-title":"J Hepatol"},{"key":"ref=48","unstructured":"HCV guidance: recommendations for testing, managing, and treating hepatitis C. AASLD\/IDSA2019, Available at:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/200206_HCVGuidance_November_06_2019_a.pdf\"> https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/200206_HCVGuidance_November_06_2019_a.pdf"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","volume":"16","author":"Manns M.","year":"2016","unstructured":"Manns M.; Samuel D.; Gane E.J.; Mutimer D.; McCaughan G.; Buti M.; Prieto M.; Calleja J.L.; Peck-Radosavljevic M.; M\u00fcllhaupt B.; Agarwal K.; Angus P.; Yoshida E.M.; Colombo M.; Rizzetto M.; Dvory- Sobol H.; Denning J.; Arterburn S.; Pang P.S.; Brainard D.; McHutchison J.G.; Dufour J.F.; Van Vlierberghe H.; van Hoek B.; Forns X.; Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis SOLAR-2 investigators2016,16(6),685-697","journal-title":"Lancet Infect Dis"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/S0168-8278(15)30015-5","volume":"62","author":"Jacobson I.M.","year":"2015","unstructured":"Jacobson I.M.; Poordad F.; Firpi-Morell R.; Everson G.T.; Efficacy and safety of GZR and EBR in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT part A). J Hepatol 2015,62(Suppl. 2),S193-S194","journal-title":"J Hepatol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","volume":"65","author":"Belli L.S.","year":"2016","unstructured":"Belli L.S.; Berenguer M.; Cortesi P.A.; Strazzabosco M.; Rockenschaub S.R.; Martini S.; Morelli C.; Donato F.; Volpes R.; Pageaux G.P.; Coilly A.; Fagiuoli S.; Amaddeo G.; Perricone G.; Vinaixa C.; Berlakovich G.; Facchetti R.; Polak W.; Muiesan P.; Duvoux C.; Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol European Liver and Intestine Association (ELITA)2016,65(3),524-531","journal-title":"J Hepatol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"Charlton M.","year":"2015","unstructured":"Charlton M.; Everson G.T.; Flamm S.L.; Kumar P.; Landis C.; Brown R.S.; Fried M.W.; Terrault N.A.; O\u2019Leary J.G.; Vargas H.E.; Kuo A.; Schiff E.; Sulkowski M.S.; Gilroy R.; Watt K.D.; Brown K.; Kwo P.; Pungpapong S.; Korenblat K.M.; Muir A.J.; Teperman L.; Fontana R.J.; Denning J.; Arterburn S.; Dvory-Sobol H.; Brandt-Sarif T.; Pang P.S.; McHutchison J.G.; Reddy K.R.; Afdhal N.; SOLAR-1 Investigators. LDV and SOF plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015,149,649-659","journal-title":"Gastroenterology"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.28926","volume":"65","author":"Chhatwal J.","year":"2017","unstructured":"Chhatwal J.; Samur S.; Kues B.; Ayer T.; Roberts M.S.; Kanwal F.; Hur C.; Donnell D.M.; Chung R.T.; Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology 2017,65(3),777-788","journal-title":"Hepatology"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","volume":"60","author":"Fabrizi F.","year":"2015","unstructured":"Fabrizi F.; Verdesca S.; Messa P.; Martin P.; Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 2015,60(12),3801-3813","journal-title":"Dig Dis Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","volume":"95","author":"Jadoul M.","year":"2019","unstructured":"Jadoul M.; Bieber B.A.; Martin P.; Akiba T.; Nwankwo C.; Arduino J.M.; Goodkin D.A.; Pisoni R.L.; Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019,95(4),939-947","journal-title":"Kidney Int"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jhep.2017.12.003","volume":"68","author":"S\u00f6derholm J.","year":"2018","unstructured":"S\u00f6derholm J.; Millbourn C.; B\u00fcsch K.; K\u00f6vamees J.; Schvarcz R.; Lindahl K.; Bruchfeld A.; Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol 2018,68(5),904-911","journal-title":"J Hepatol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jvh.12185","volume":"21","author":"van der Meer A.J.","year":"2014","unstructured":"van der Meer A.J.; Veldt B.J.; Feld J.J.; Wedemeyer H.; Dufour J.F.; Lammert F.; Duarte-Rojo A.; Manns M.P.; Zeuzem S.; Hofmann W.P.; de Knegt R.J.; Hansen B.E.; Janssen H.L.; The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat 2014,21(8),568-577","journal-title":"J Viral Hepat"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.29258","volume":"66","year":"2017","unstructured":"Saxena, V1.; Khungar, V.; Verna, EC.; Levitsky, J.; Brown, RS Jr.; Hassan, MA.; Sulkowski, MS.; O\u2019Leary, JG.; Koraishy, F.; Galati, JS.; Kuo, AA.; Vainorius, M.; Akushevich, L.; Nelson, DR.; Fried, MW.; Terrault, N.; Reddy, KR. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology 2017,66,1090-1101","journal-title":"Hepatology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1111\/hdi.12643","volume":"22","author":"Cohen-Bucay A.","year":"2018","unstructured":"Cohen-Bucay A.; Francis J.M.; Gordon C.E.; Timing of hepatitis C virus infection treatment in kidney transplant candidates. Hemodial Int 2018,22(Suppl. 1),S61-S70","journal-title":"Hemodial Int"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"Reig M.","year":"2016","unstructured":"Reig M.; Mari\u00f1o Z.; Perell\u00f3 C.; I\u00f1arrairaegui M.; Ribeiro A.; Lens S.; D\u00edaz A.; Vilana R.; Darnell A.; Varela M.; Sangro B.; Calleja J.L.; Forns X.; Bruix J.; Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016,65(4),719-726","journal-title":"J Hepatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"Conti F.","year":"2016","unstructured":"Conti F.; Buonfiglioli F.; Scuteri A.; Crespi C.; Bolondi L.; Caraceni P.; Foschi F.G.; Lenzi M.; Mazzella G.; Verucchi G.; Andreone P.; Brillanti S.; Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016,65(4),727-733","journal-title":"J Hepatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4254\/wjh.v10.i2.267","volume":"10","author":"Butt A.S.","year":"2018","unstructured":"Butt A.S.; Sharif F.; Abid S.; Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: biologically plausible or an epiphenomenon? World J Hepatol 2018,10(2),267-276","journal-title":"World J Hepatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/hep.29911","volume":"68","author":"Faillaci F.","year":"2018","unstructured":"Faillaci F.; Marzi L.; Critelli R.; Milosa F.; Schepis F.; Turola E.; Andreani S.; Vandelli G.; Bernabucci V.; Lei B.; D\u2019Ambrosio F.; Bristot L.; Cavalletto L.; Chemello L.; Sighinolfi P.; Manni P.; Maiorana A.; Caporali C.; Bianchini M.; Marsico M.; Turco L.; de Maria N.; Del Buono M.; Todesca P.; di Lena L.; Romagnoli D.; Magistri P.; di Benedetto F.; Bruno S.; Taliani G.; Giannelli G.; Martinez-Chantar M.L.; Villa E.; Liver angiopoietin is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals. Hepatology 2018,68(3),1010-1024","journal-title":"Hepatology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2017.10.035","volume":"154","author":"Debes J.D.","year":"2018","unstructured":"Debes J.D.; van Tilborg M.; Groothuismink Z.M.A.; Hansen B.E.; Schulze Zur Wiesch J.; von Felden J.; de Knegt R.J.; Boonstra A.; Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology 2018,154(3),515-517.e3","journal-title":"Gastroenterology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.20517\/2394-5079.2019.19","volume":"5","author":"Rutledge S.M.","year":"2019","unstructured":"Rutledge S.M.; Zheng H.; Li D.K.; Chung R.T.; No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatoma Res 2019,5,31","journal-title":"Hepatoma Res"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/189127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/189127\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/189127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:46:40Z","timestamp":1632502000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/189127\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221999201214224126","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}